Otonomy, Inc. Logo
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
21 mai 2015 16h05 HE | Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067 Achieved statistical significance on...